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ABSTRACT
Objectives The enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1) plays a well- 
characterised role in the metabolism and activation of 
endogenous glucocorticoids (GCs). However, despite 
its potent upregulation at sites of inflammation, its 
role in peripheral metabolism and action of therapeutic 
GCs remains poorly understood. We investigated the 
contribution of 11β-HSD1 to the anti- inflammatory 
properties of the active GC corticosterone, administered 
at therapeutic doses in murine models of polyarthritis.
Methods Using the tumour necrosis factor- tg and K/
BxN serum- induced models of polyarthritis, we examined 
the anti- inflammatory properties of oral administration 
of corticosterone in animals with global, myeloid and 
mesenchymal targeted transgenic deletion of 11β-HSD1. 
Disease activity and joint inflammation were scored daily. 
Joint destruction and measures of local and systemic 
inflammation were determined by histology, micro- CT, 
quantitative RT- PCR, fluorescence activated cell sorting 
and ELISA.
Results Global deletion of 11β-HSD1 resulted 
in a profound GC resistance in animals receiving 
corticosterone, characterised by persistent synovitis, 
joint destruction and inflammatory leucocyte infiltration. 
This was partially reproduced with myeloid, but not 
mesenchymal 11β-HSD1 deletion, where paracrine 
GC signalling between cell populations was shown to 
overcome targeted deletion of 11β-HSD1.
Conclusions We identify an entirely novel component 
of therapeutic GC action, whereby following their 
systemic metabolism, they require peripheral reactivation 
and amplification by 11β-HSD1 at sites of inflammation 
to deliver their anti- inflammatory therapeutic effects. 
This study provides a novel mechanistic understanding of 
the anti- inflammatory properties of therapeutic GCs and 
their targeting to sites of inflammation in polyarthritis.
INTRODUCTION
Due to their anti- inflammatory actions, therapeutic 
glucocorticoids (GCs) have been widely used in the 
management of inflammation. However, despite 
their continuing widespread use, several critical 
aspects of their therapeutic action remain unclear.1 
The enzyme 11β-hydroxysteroid dehydrogenase 
type 1 (11β-HSD1) plays a well characterised role 
in the hepatic activation of structurally inactive 
GCs (such as cortisone and prednisone), converting 
them to their active counterparts (such as hydro-
cortisone and prednisolone).2 3 However, the role 
of 11β-HSD1 in mediating the anti- inflammatory, 
disease- modifying actions of therapeutic GCs 
remains poorly understood. This represents a signif-
icant barrier to our understanding of the mecha-
nisms of action of therapeutic GC action in vivo 
and to the development of GCs with an enhanced 
benefit:risk ratio.
We explore the contribution of pre- receptor 
steroid metabolism by the enzyme 11β-HSD1 to 
the anti- inflammatory actions of GCs using in vivo 
models of chronic polyarthritis. We demonstrate a 
fundamental role for the peripheral re- activation 
of GCs in mediating their anti- inflammatory prop-
erties, with mice with global 11β-HSD1 deletion 
showing a complete resistance to their therapeutic 
effects of orally administered GCs in their active 
form. These findings change our understanding of 
Key messages
What is already known about this subject?
 ► Potent anti- inflammatory glucocorticoids 
such as prednisolone are rapidly metabolised, 
and circulate in both their active and inactive 
(prednisone) forms.
 ► Enzymes such as 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), which is 
potently upregulated at sites of inflammation, 
reactivates inactive glucocorticoids such as 
prednisone.
What does this study add?
 ► This study demonstrates that following 
their oral delivery and systemic metabolism, 
the anti- inflammatory properties of active 
glucocorticoids are completely dependent on 
their peripheral reactivation by 11β-HSD type 1.
 ► The global deletion of 11β-HSD type 1 results in 
profound therapeutic glucocorticoid resistance.
How might this impact on clinical practice or 
future developments?
 ► This study provides a novel mechanistic 
understanding of the anti- inflammatory 
properties of therapeutic glucocorticoids and 
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how many structurally active therapeutic GCs elicit their anti- 
inflammatory effects, requiring peripheral reactivation by the 
enzyme 11β-HSD1, after their initial systemic inactivation, to 
mediate their beneficial immune- modulatory effects.
MATERIALS AND METHODS
Models of polyarthritis
The tumour necrosis factor (TNF)- tg model of chronic inflamma-
tory polyarthritis, obtained courtesy of Professor George Kollias 
(BSRC Fleming, Athens), was maintained on a C57BL/6 back-
ground and compared with WT littermates.4 At day 32 of age, 
at the first onset of measurable polyarthritis, male TNF- tg mice 
received drinking water supplemented with either corticosterone 
(Cort) (100 µg/mL, 0.66% ethanol), or vehicle (0.66% ethanol) 
for 3 weeks. Mice were scored as previously described.5 6 At day 
53, serum was collected by cardiac puncture and tissues excised 
for analysis. Serum transfer- induced arthritis (STIA) was induced 
by intravenous injection of 100 µL arthritogenic serum from 
KRN mice (K/BxN).7 Ankle or wrist joint thickness was moni-
tored using callipers and reported as the change from baseline.
Targeted deletion of 11β-HSD1
11β-HSD1 KO animals with global 11β-HSD1 deletion were 
crossed with TNF- tg animals to generate TNF‐tg11βKO animals 
as previously described.8 Mesenchymal 11β-HSD1 KO animals 
were generated by crossing flx/flx- HSD11B1 mice with 
Twist2- cre mice to generate 11βHSD1flx/flx/Twist2cre animals, 
which were paired with TNF- tg animals to produce TNF- 
tg11βHSD1flx/flx/Twist2cre (TNF- tg11βflx/tw2cre).9–11 Myeloid targeted 
11β-HSD1 KO animals were generated by crossing flx/flx- 
HSD11B1 mice with LysM- cre mice to generate 11βHSD1flx/
flx/LysMcre animals, which were paired with TNF- tg animals to 
produce TNF- tg11βHSD1flx/flx/LysMcre (TNF- tg11βflx/LysMcre).12
11β-HSD1 activity
11β-HSD1 activity was determined by thin- layer chromatog-
raphy as previously reported.8 13 Briefly, ex vivo tissue biop-
sies and in vitro cultures were incubated with 100 nmol/L of 
11- dehydrocorticosterone (11- DHC) and tritiated [3H] tracer. 
Steroid conversion was measured using a Bioscan imager 
(Bioscan, Washington, District of Columbia, USA) and fractional 
conversion calculated.
Primary fibroblast-like synoviocytes and macrophage culture
Primary fibroblast- like synoviocytes (FLS) were isolated from 
combined hind legs and front paws from mice following dissec-
tion and cleaning of tissue as previously reported.13 Briefly, joints 
were digested in RPMI containing 2% fetal calf serum (FCS), 
2.5 mg/mL collagenase D (Roche) and 20 µg/mL DNase (Sigma‐
Aldrich) for 45 min at 37°C with agitation. After filtering, cells 
were cultured in RPMI containing 10% FCS and 1% pen- strep 
and cultured to passage 3 before use. Primary murine peritoneal 
macrophages were isolated by CD11b+ve selection with CD11b 
MicroBeads (Miltenyi Biotec, Surrey, UK) following peritoneal 
lavage in phosphate- buffered saline, and maintained in Dulbec-
co's Modified Eagle Medium containing 10% FCS and 1% pen- 
strep and maintained for up to 48 hours.
Gene expression analysis
Gene expression was assessed by TaqMan Gene Expression 
Assays (ThermoFisher Scientific) following mRNA isolation 
by innuPREP RNA Mini Kit (Analytikjena, Cambridge) and 
reverse transcription (Multiscribe, ThermoFisher Scientific) as 
per the manufacturer’s guidelines. Ccl2, cxcl2, Cxcl10, Tnfα, 
il1β, Il6 and gilz were determined using species- specific probe 
sets by real- time PCR on an ABI7500 system (Applied Biosys-
tems, Warrington, UK). mRNA abundance was normalised to 
either 18S or Gapdh. Data, obtained as Ct values and ΔCt deter-
mined (Ct target–Ct 18S/GAPDH), were expressed as arbitrary 
units (AU) using the following transformation: (arbitrary units 
(AU)=1000×(2−Δct)).
ELISA analysis
Serum interleukin (IL)-6 and corticosterone (R&D Systems, 
Abingdon, UK) were determined using commercially available 
ELISA assays in accordance with the manufacturer’s instructions.
Histological analysis of joints
Histochemistry was performed on paraffin- embedded 10 µm 
sections. Pannus size at the humerus/ulna joint interface and 
osteoclast numbers on the bone surface pannus (following tartra-
teresistant acid phosphatase (TRAP) staining) were determined 
using ImageJ software as previously reported.5 14 For quantifi-
cation, the mean of three adjacent 10 µm sections cut from the 
centre of the joint from six animals were assessed.
MicroCT morphometry analysis
Front paws from mice were imaged using a Skyscan 1172 
micro- CT scanner (Bruker) using X- ray beam settings of 60 
kV/167 μA with a 0.5 mm aluminium filter. Projections were 
taken every 0.45° at 580 ms exposure. Image volumes were 
reconstructed using the Feldkamp algorithm (NRecon V.1.6.1.5, 
Bruker) having applied beam hardening correction. Front paws 
were reconstructed and MeshLab V.1.3.2 was used to generate 
meshes which could then be scored for bone erosions as described 
previously.5
Serum steroid measurements
Serum samples were collected by cardiac bleeds to assess 
systemic metabolism between groups; 200 µL of serum was 
spiked with 0.2 ng of internal standard (corticosterone- d8 and 
cortisol- d4; purchased from Sigma- Aldrich, UK). Steroids were 
extracted via liquid- liquid extraction with 2 mL of tert- methyl 
butyl ether (MTBE). MTBE was evaporated to dryness under 
nitrogen at 55°C. Samples were reconstituted in 125 µL of 
50/50 methanol/water for liquid chromatography tandem mass 
spectrometry analysis.15 16 Samples were measured on a Waters 
Xevo- XS mass spectrometer coupled to an Acquity uPLC with 
an electrospray ionisation source in positive ionisation mode. 
Steroids were identified by comparison to authentic reference 
standards, (Sigma- Aldrich), with matching retention time and 
identical mass transitions and quantified relative to a calibration 
series. Concentrations were calculated relative to internal stan-
dard corticosterone to corticosterone- d8 and 11- DHC and its 
isomer metabolite to cortisol- d4.
Tissue digestion and flow cytometric analysis of synoviocytes
One hind leg and one front paw per mouse was dissected and 
cleaned of tissue as previously reported.8 Briefly, joints were 
digested in RPMI containing 2% FCS, 2.5 mg/mL collagenase 
D (Roche) and 20 µg/mL DNase (Sigma‐Aldrich) for 45 min 
at 37°C with agitation. After filtering, cells were centrifuged, 
red cells lysed and cells counted before being filtered through 
40 µm cell strainer, incubated with anti- CD16/CD32 blocking 
antibody (1:200; eBioscience) for 10 min at RT, followed by 
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staining are outlined in online supplemental table 1). Data were 
acquired using a BD LSR Fortessa X20 and analysed using 
FlowJo software (FlowJo). The following gating strategy was 
used for myeloid cells: live cells were gated on CD45+CD11b+ 
cells. Neutrophils identified as Ly6g+, macrophages were 
Ly6g−, F4/80+ and inflammatory activated M1- like macro-
phages were F4/80+MHC class II+. T cells were identified as 
live CD45+CD3+. CD3+ cells were then stratified as CD4+ 
or CD8+ T cells. B cells were identified as CD45+CD3 and 
CD19+.
Statistical analysis
Statistical significance was defined as p<0.05 using either an 
unpaired Student’s t- test or two- way analysis of variance with Tukey 
post hoc analysis where a Gaussian distribution was identified.
Figure 1 (A) Total clinical scores (arbitrary units (AU)), (B) arthritic paw scores (AU) and (C) representative images of synovitis at the ulna/humerus 
joint interface of wild- type (WT), tumour necrosis factor (TNF)- tg, 11βKO and TNF- tg11βKO animals receiving either vehicle or corticosterone (100 µg/
mL) in the drinking water for 3 weeks. (B) of TNF- tg and TNF- tg11βKO animals receiving vehicle or corticosterone (100 µg/mL) in the drinking water 
for 3 weeks. (D) Serum levels of interleukin (IL)-6 determined by ELISA, (E) histological scoring of synovitis (AU), (F) representative images of TRAP 
stained osteoclasts at the ulna/humerus joint interface, (G) osteoclast number (AU) at the ulna/humerus joint interface, (H) quantification of bone 
erosion (AU) in the wrist, metacarpals and phalanges of WT, TNF- tg, 11βKO and TNF- tg11βKO animals receiving either vehicle or corticosterone (100 µg/
mL) in the drinking water for 3 weeks. (I) representative images of three- dimensional reconstructions of front paws of TNF- tg and TNF- tg11βKO animals 
receiving vehicle or corticosterone (100 µg/mL) in the drinking water for 3 weeks, red arrows indicate erosions. (J) Total clinical scores (AU), (K) 
arthritic paw scores (AU) and swelling (mm) of (L) back paws and (M) ankles of WT and 11βKO animals after induction of arthritis with K/BxN serum 
receiving either vehicle or corticosterone (100 µg/mL) in the drinking water for 1 week. Values are expressed as mean±SE, n=6 per group for all TNF- tg 
experiments and n=5 (K/BxN), n=6 (K/BxN/Cort), n=6 (K/BxN11βKO) and n=5 (K/BxN11βKO/Cort). Statistical significance was determined using two- way 
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RESULTS
11β-HSD1 KO animals are resistant to therapeutic GCs
We crossed the TNF- tg murine model of chronic polyarthritis 
onto the 11βKO background to generate TNF- tg animals with 
deletion of 11β-HSD1 (TNF‐tg11βKO). Wild- type (WT), TNF- tg, 
11βKO and TNF‐tg11βKO animals received either vehicle or corti-
costerone in drinking water at 50 and 100 µg/mL as previously 
reported.2 14 17 At 50 µg/mL, no significant change in disease 
activity or joint inflammation were apparent in TNF- tg animals 
and was discontinued from the study (online supplemental figure 
1A‒C). At 100 µg/mL corticosterone resulted in a significant 
reduction in clinical scores and joint inflammation in TNF- tg 
animals (figure 1A,B). In contrast, anti- inflammatory effects of 
corticosterone were absent in TNF‐tg11βKO animals. Similarly, 
serum IL-6 was reduced in TNF- tg mice receiving corticoste-
rone (p<0.05), which was absent in TNF‐tg11βKO counterparts 
(figure 1D). TNF- tg mice receiving corticosterone showed a 
marked reduction in pannus invasion and osteoclast numbers at 
the pannus bone interface, which was entirely absent in TNF‐
tg11βKO animals (figure 1C–G). Micro- CT analysis of juxta- 
articular erosions confirmed that corticosterone significantly 
reduced joint destruction in TNF- tg mice, but not TNF‐tg11βKO 
animals (figure 1H,I). In the KBxN serum induction model of 
polyarthritis, similar patterns were observed with total clinical 
scores and joint inflammation scores being reduced by corticos-
terone in WT, but not in 11βKO animals at day 6 (figure 1J–M). 
Here, at early time points (days 3–4) GCs were able to partially 
suppress clinical scores of disease, including weight loss and leth-
argy in 11βKO animals, without impacting on measures of joint 
inflammation and swelling. These data demonstrate that GC 
activation by the enzyme 11β-HSD1 is a necessary step in medi-
ating the anti- inflammatory actions of the GC corticosterone in 
the joints of animals with polyarthritis.
Oral corticosterone generates circulating 11-DHC substrate 
for 11β-HSD1 activation
Metabolism and inactivation of therapeutic GCs by renal 
11β-HSD2 creates a circulating pool of inactive GC (corti-
costerone to 11- DHC in mice) available for peripheral activa-
tion by 11β-HSD1. To assess the systemic metabolism of oral 
administered corticosterone, we measured serum levels of the 
corticosterone and its inactive derivative 11- DHC. No differ-
ences were observed in daily intake of corticosterone between 
groups, determined by quantifying daily drinking water intake 
per mouse, with an average exposure of 22.5+1.44 µg/g of body 
weight. Here, serum corticosterone and 11- DHC were detected 
and significantly increased following administration of corticos-
terone, with exposure comparable across groups (figure 2A,B). 
In all groups, exposure to corticosterone resulted in a signifi-
cant reduction in adrenal weights relative to vehicle (figure 2C). 
Analysis of corticosterone inactivation by the 11β-HSD enzymes 
within the synovium was assessed by thin layer chromatog-
raphy in WT, TNF- tg, 11βKO, TNF- tg anNFtg11βKO animals and 
showed no significant variation between groups (online supple-
mental figure 2). These data confirm a comparable increase in 
serum corticosterone and inactive 11- DHC in TNF- tg and TNF‐
tg11βKO animals receiving oral corticosterone.
Effects of oral corticosterone on leucocyte recruitment are 
dependent on 11β-HSD1
We examined infiltrating leucocytes and inflammatory media-
tors in synovial tissue digests to assess their regulation by corti-
costerone. Here, while corticosterone resulted in a significant 
decrease in total leucocytes, neutrophils, macrophages, CD8+ 
and CD19+, but not CD3+ and CD4+ populations in TNF- tg 
mice, TNF‐tg11βKO animals were resistant to the actions of 
corticosterone on many of these parameters, with no apparent 
reduction in total leucocytes, macrophages and neutrophils 
(figure 3A–D). TNF‐tg11βKO animals receiving corticosterone 
also possessed significantly higher numbers of total leucocytes, 
neutrophils, macrophages, CD3+ (p<0.01) and CD4+ cell 
populations relative to TNF- tg counterparts receiving corti-
costerone (figure 3A–E). Here, corticosterone skewed macro-
phage polarisation, with reduced numbers of inflammatory 
activated M1- like polarised or macrophages relative to total 
macrophages, TNF- tg animals, while TNF‐tg11βKO animals 
showed complete resistance to this effect (figure 3H). However, 
TNF‐tg11βKO animals retained an effective suppression of both 
CD8+ and CD19+ cell populations in response to corticos-
terone (figure 3F–H). Analysis of gene expression in synovial 
tissue digests revealed a significant reduction in the chemokines 
Ccl2, Cxcl10 and cytokine Il- 1b, and an increased expression of 
Figure 2 (A, B) Serum corticosterone and 11- dehydrocorticosterone (11- DHC) determined by liquid chromatography tandem mass spectrometry 
(LCMS) from tumour necrosis factor (TNF)- tg, 11βKO and TNF- tg11βKO animals receiving either vehicle or corticosterone (100 µg/mL) in the drinking 
water for 3 weeks. (C) Adrenal weights in wild- type (WT), TNF- tg, 11βKO and TNF- tg11βKO animals receiving either vehicle or corticosterone (100 µg/
mL) in the drinking water for 3 weeks. Values are expressed as mean±SE, n=6 per group for ELISA and adrenal weights and n=3 per group for LCMS. 
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anti- inflammatory Gilz expression in TNF- tg animals receiving 
corticosterone, which was entirely absent in TNF‐tg11βKO animals 
(figure 3I–N). These data reveal that TNF‐tg11βKO animals show 
marked resistance to the anti- inflammatory properties of thera-
peutic GCs on leucocyte recruitment and on regulation of local 
inflammatory mediators.
Mice with stromal deletion of 11β-HSD1 retain anti-
inflammatory responses to GCs
Given the stromal upregulation of stromal 11β-HSD1 sites of 
inflammation, we wished to delineate its specific contribution 
to GC resistance in the TNF- tg11βflx/tw2cre mouse relative to 
TNF- tg littermates, where we have previously reported effective 
mesenchymal deletion.3 8 A significant reduction in 11β-HSD1 
activity was apparent in primary fibroblasts and osteoblasts 
isolated from TNF- tg11βflx/tw2cre animals, while activity was 
retained in non mesenchyme derived tissues such as livers and 
spleen (figure 4A,B). Suppression of adrenal weights was apparent 
across all groups in response to corticosterone (figure 4C). 
Corticosterone significantly reduced clinical scores and measures 
of joint inflammation in both TNF- tg11βflx/tw2cre and TNF- tg 
littermates (figure 4D,E). While circulating levels of the acute 
response cytokine IL-6, remained elevated in TNF- tg11βflx/tw2cre 
receiving corticosterone, analysis of pannus invasion, osteoclast 
numbers and joint destruction by micro- CT, indicated that corti-
costerone was equally effective at suppressing disease activity 
Figure 3 Cell numbers of (A) total leucocytes, (B) neutrophils, (C) macrophages, (D) CD3+ populations, (E) CD4+ populations, (F) CD8+ populations, 
(G) CD19+ populations and (H) the M1- like/total macrophage ratio determined by flow cytometry in tumour necrosis factor (TNF)- tg and TNF- tg11βKO 
animals receiving vehicle or corticosterone (100 µg/mL) in the drinking water for 3 weeks. Gene expression (AU) of (I) Ccl2, (J) Cxcl2, (K) Cxcl10, (L) 
Il-1, (M) mTnf and (N) Gilz determined by quantitative PCR in tibia isolated from TNF- tg and TNF- tg11βKO animals receiving vehicle or corticosterone 
(100 µg/mL) in the drinking water for 3 weeks. Values are expressed as mean±SE, n=6 per group. Statistical significance was determined using two- 
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in both TNF- tg and TNF- tg11βflx/tw2cre animals (figure 4C,G–L). 
Consequently, despite effective deletion of 11β-HSD1 in the 
mesenchymal compartment, TNF- tg11βflx/tw2cre animals retain a 
robust anti- inflammatory response to corticosterone.
Partial GCs resistance with myeloid deletion of 11β-HSD1
At sites of inflammation, 11β-HSD1 is highly expressed in macro-
phages and is implicated in regulating their anti- inflammatory 
properties.3 18 19 We used the LysMCre mouse (targeted towards 
neutrophils, macrophages and granulocytes) to generate tg11βflx/
LysMcre animals with a deletion of 11β-HSD1 in the myeloid 
compartment.12 11β-HSD1 activity was significantly reduced in 
both peripheral blood mononuclear cell and peritoneal macro-
phages relative to WT counterparts (figure 5A). In contrast, 
normal 11β-HSD1 activity was apparent in tissues such as 
muscle, fat and liver (figure 5A,B). Corticosterone significantly 
reduced adrenal weights in both TNF- tg11βflx/LysMcre animals and 
TNF- tg littermate controls of (figure 5C). TNF- tg11βflx/LysMcre 
mice receiving corticosterone showed a significant reduction in 
joint inflammation scores but not in total clinical scores, while 
serum IL-6 levels were similarly decreased in both TNF- tg and 
TNF- tg11βflx/LysMcre (figure 4D–F). A, significant reductions in 
both pannus size and osteoclast numbers were apparent in both 
TNF- tg and TNF- tg11βflx/LysMcre animals receiving corticoste-
rone (figure 5G–J). However, evidence of residual pannus and 
osteoclast numbers in TNF- tg11βflx/LysMcre animals was supported 
by a greater incidence of juxta- articular joint destruction deter-
mined by micro- CT relative to TNF- tg counterparts (p<0.05) 
(figure 5K,L). These data demonstrate that mice with a myeloid 
targeted deletion of 11β-HSD1 retain the capacity to respond to 
therapeutic GCs.
Figure 4 Corticosterone production (pmol/mg tissue/hour) in (A) fibroblast- like synoviocytes (FLS) and osteoblasts (OBs) cultures and (B) liver and 
spleen ex vivo biopsies isolated from tumour necrosis factor (TNF)- tg and TNF- tg11βflx/tw2cre mice determined by scanning thin layer chromatography. 
(C) Adrenal weights (mg), (D) total clinical scores (AU), (E) arthritic paw scores (arbitrary units (AU)), (F) serum IL-6 determined by ELISA, (G) 
histological scoring (AU) and (H) representative images of synovitis at the ulna/humerus joint interface, (I) histological scoring (AU) and (J) 
representative images of TRAP stained osteoclast numbers at the ulna/humerus joint interface, (K) quantification of bone erosion (AU) in the wrist, 
metacarpals and phalanges and (L) representative images of three- dimensional reconstructions of front paws in TNF- tg and TNF- tg TNF- tg11βflx/tw2cre 
animals receiving either vehicle or corticosterone (100 µg/mL) in the drinking water for 3 weeks. Values are expressed as mean±SE, n=6 per group. 
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Paracrine GC signalling compensates for cell-specific 
11β-HSD1 deletion
Given our findings in the stromal and myeloid targeted models, 
we performed co- culture experiments in FLS and macrophage 
to determine if GCs activated in one cell population could 
influence the other by paracrine signalling. We generated condi-
tioned media by exposing WT and 11β-HSD1 KO FLS to the 
inactive GC 11- DHC for 24 hours, which was then placed on 
11β-HSD1 KO macrophages for a further 24 hours prior to 
measuring GC response genes (figure 6A). Here, 11β-HSD1 KO 
macrophages responded to conditioned media from WT FLS 
exposed to 11- DHC (increasing Gilz and suppressing IL-6), but 
not conditioned media from 11β-HSD1 KO FLS (figure 6B,C). 
Conditioned media from WT and 11β-HSD1 KO macrophages 
conditioned with 11- DHC were then placed on 11β-HSD1 KO 
FLS for 24 hours and GC responsive gene analysed (figure 6D). 
11β-HSD1 KO FLS responded to conditioned media from 
WT macrophages exposed to 11- DHC (increasing Gilz and 
suppressing IL-6), but did not respond to conditioned media 
generated in 11β-HSD1 KO macrophages (figure 6E,F). Simi-
larly, IL-6 production in 11β-HSD1 KO FLS was suppressed in 
response to media from WT macrophages exposed to 11- DHC, 
but not from 11β-HSD1 KO macrophages exposed to 11- DHC 
(figure 6G). These data confirm that 11β-HSD1 can mediates 
paracrine GC signalling between distinct cell populations present 
at sight of inflammation, including macrophages and FLS.
DISCUSSION
Despite the potent upregulation of 11β-HSD1 at sites of inflam-
mation, its roles in mediating the effects of active therapeutic 
GCs have remained poorly understood.19–22 Here, studies by 
Schmidt et al and Hardy et al reported increasing levels of 
11β-HSD1 within FLS and synovial macrophages that correlated 
with inflammation. Using murine models of polyarthritis, we 
have identified an entirely novel and, until now, unrecognised 
Figure 5 Corticosterone production (pmol/mg tissue/hour) in (A) tibialis anterior (TA) muscle, fat and liver ex vivo biopsies and (B) monocyte, 
peripheral blood mononuclear cell (PBMC)- derived macrophages and resident macrophages isolated from tumour necrosis factor (TNF)- tg and TNF- 
tg11βflx/LysMcre mice determined by scanning thin layer chromatography. (C) Adrenal weights (mg), (D) total clinical scores (arbitrary units (AU)), (E) 
arthritic paw scores (AU), (F) serum interleukin (IL)-6 determined by ELISA, (G) histological scoring (AU) and (H) representative images of synovitis at 
the ulna/humerus joint interface, (I) histological scoring (AU) and (J) representative images of TRAP stained osteoclast numbers at the ulna/humerus 
joint interface, (K) quantification of bone erosion (AU) in the wrist, metacarpals and phalanges and (L) representative images of three- dimensional 
reconstructions of front paws in TNF- tg and TNF- tg11βflx/LysMcre animals receiving either vehicle or corticosterone (100 µg/mL) in the drinking water for 3 
weeks. Values are expressed as mean±SE, n=6 per group. Statistical significance was determined using two- way analysis of variance with Tukey post 
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component of therapeutic GC action, whereby they require 
peripheral reactivation by 11β-HSD1 at sites of inflammation 
to deliver anti- inflammatory effects (figure 7). Here, the global 
transgenic deletion of 11β-HSD1 prevents this critical step, 
resulting in severe GC resistance in both TNF- tg and K/BxN 
models of polyarthritis.
The importance of endogenous GC metabolism by 11β-HSD1 
in the pathophysiology of inflammatory polyarthritis are well 
established.8 18 23 We used oral corticosterone to suppress 
disease activity and joint inflammation in murine models of 
polyarthritis.2 14 24 We observed effective suppression at 100 µg/
mL in the drinking water, where daily intake of corticosterone 
was 22.5 µg/g in the mice, and would be estimated to equate 
to administration of 40 mg hydrocortisone or 10 mg of pred-
nisolone per day in an adult. Here, total active corticosterone 
and inactive 11- DHC, increased in TNF- tg and TNF‐tg11βKO 
mice, with the reduced transcortin binding affinity of 11- DC 
predicted to further elevate its circulating free levels.25 In the 
models of polyarthritis, disease activity, synovitis and joint 
destruction were markedly suppressed in animals receiving 
corticosterone. However, we observed a profound GC resis-
tance in 11β-HSD1 KO animals, despite equivalent serum 
exposure to corticosterone and 11- DHC. While these animals 
with deletion of 11β-HSD1 retained a capacity to respond to 
Figure 6 (A) Schematic representation of conditioned media experiments in which media from wild- type (WT) and 11βKO fibroblast- like 
synoviocytes (FLS) treated with either vehicle or dehydrocorticosterone (DHC) is used to treat 11βKO macrophages. Gene expression (arbitrary units 
(AU)) of (B) Gilz and (C) Il-6 in 11βKO macrophages treated with conditioned media from WT and 11βKO FLS determined by quantitative PCR (qPCR). 
(D) Schematic representation of conditioned media experiments in which media from WT and 11βKO macrophages treated with either vehicle or 
DHC is used to treat 11βKO FLS. Gene expression (AU) of (E) Gilz and (F) Il-6 in 11βKO FLS treated with conditioned media from WT and 11βKO 
macrophages determined by qPCR. (G) Protein levels of IL-6 (ng/mL) in the media of 11βKO FLS treated with conditioned media from WT and 11βKO 
macrophages determined by ELISA. Values are expressed as mean±SE, n=3 per group. Statistical significance was determined using one- way analysis 
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oral corticosterone, with evidence of a GC- mediated adrenal 
suppression and limited improvements in body weight and pain 
behaviour in the K/BxN model, these levels were insufficient to 
mediate anti- inflammatory actions within the joint. This indi-
cates that the peripheral metabolism and activation of GCs 
such as corticosterone by 11β-HSD1 are required to mediate 
their anti- inflammatory properties. In this study, we used the 
GC corticosterone in our models as, within mice, it possesses 
equivalent action and metabolism as the steroid hydrocortisone 
in humans. Further research is now required to examine how 
synthetic GCs such as prednisolone and prednisone are metab-
olised by 11β-HSD1 at sites of inflammation in murine models 
and in human disease cohorts. This is of particular interest in 
human inflammatory disease, with Schmidt et al reporting shifts 
towards reduced synovial GC activation in synoviocytes in rheu-
matoid arthritis (RA) relative to osteoarthritis.20 This appeared 
to occur secondary to a shift in the 11β-HSD1/11β-HSD2 ratio, 
favouring steroid inactivation and was potentially attributed to 
a loss of sympathetic nerve fibre signalling to the RA joint. Anal-
ysis of synovial tissue shed light on the mechanism of GC resis-
tance in the TNF‐tg11βKO mouse. A key mechanism of action of 
therapeutic GC in the inflamed synovium is the suppression of 
leucocyte recruitment and reduction in pro- inflammatory cyto-
kines and chemokines through suppression of pro- inflammatory 
pathways.26–28 In this feature of anti- inflammatory GC action, 
there remains ongoing debate in relation to the relative contribu-
tions of transactivation and transrepression as mechanism under-
lying the anti- inflammatory effects of GCs.29 In this study, we 
were unable to assess whether the anti- inflammatory properties 
of GC metabolism by 11β-HSD1 were predominantly mediated 
by transrepression or transactivation, which remains a promi-
nent area of interest and the focus of prominent reviews in the 
field.1 In TNF‐tg11βKO animals, expression of pro- inflammatory 
mediators persisted at sites of inflammation in response to 
corticosterone, with increased inflammatory activated M1- like 
polarisation, revealing a critical role for therapeutic GC metab-
olism by 11β-HSD1 in this process. These data suggest that in 
response to therapeutic GCs, 11β-HSD1 may mediates a shift 
from inflammatory activated M1- like macrophages to M2- like 
polarisation. However, the precise nature of these changes 
in this setting remains complex and is the subject, requiring 
more detailed characterisation, which in itself is the feature of 
Figure 7 At therapeutic doses, the glucocorticoid corticosterone requires peripheral reactivation by 11β-hydroxysteroid dehydrogenase type 
1 (11β-HSD1) at sites of inflammation, which is potently upregulated by pro- inflammatory factors such as tumour necrosis factor (TNF)-α and 
interleukin (IL)-1β, to enable their anti- inflammatory effects. The deletion of 11β-HSD1 (shown below the dashed line) prevents this critical step, 
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a notable systematic review by Tardito et al.30 Of interest, we 
observed that several leucocyte population, including CD8 T 
cells and CD19 B cells within the synovium of 11β-HSD1 KO 
animals retained responsiveness to oral corticosterone and were 
suppressed to a similar degree as WT counterparts. These data 
indicate that certain leucocyte populations retain the capacity 
to respond to circulating levels of active corticosterone, present 
even in the absence of 11β-HSD1, suggesting they possess a 
lower GC receptor activation threshold that is independent of 
11β-HSD1.
Given that FLS and macrophages highly express 11β-HSD1 
in inflammatory environments, we examined whether targeted 
deletion of 11β-HSD1 within mesenchymal derived FLS and 
myeloid- derived macrophages could recapitulate global steroid 
resistance. Here, despite effective 11β-HSD1 deletion in FLS, 
TNF- tg11βflx/tw2cre animals showed an entirely normal anti- 
inflammatory response to oral corticosterone, suggesting that 
GC reactivation within this subset alone was not critical to the 
anti- inflammatory properties of corticosterone. Similar find-
ings were evident in myeloid- targeted TNF- tg11βflx/LysMcre. Here 
despite effective deletion of 11β-HSD1 within macrophages, 
TNF- tg11βflx/LysMcre animals retained the capacity to respond to 
corticosterone. However, their response did appear to be muted, 
with disease activity scores being greater than TNF- tg counter-
parts, and with evidence of persistent joint destruction despite 
exposure to therapeutic GCs. The contribution of 11β-HSD1 
within further leucocyte populations such as T cells to corticos-
terone resistance in the global KO deserve further scrutiny in this 
context but went beyond the scope of this study.
However, these data may suggest that the autocrine ampli-
fication of GCs by 11β-HSD1 within fibroblasts or macro-
phages alone is insufficient to mediate the anti- inflammatory 
actions of therapeutic GCs in vivo, as occurs with cell- 
targeted GC receptor KO studies.31–33 Instead, we explored 
whether paracrine signalling between macrophages and FLS 
might overcome cell- targeted deletion of 11β-HSD1 using 
in vitro models. These experiments revealed that metabo-
lism of 11- DHC by 11β-HSD1 could mediate paracrine GC 
signalling between FLS and macrophages, compensating for 
cell- targeted deletion of 11β-HSD1 and reversing steroid 
resistance. Consequently, it may be that targeting any one 
cell population is insufficient to reproduce the phenotype 
observed with global 11β-HSD1 deletion. Ultimately, it is 
important to note that results observed in animal models are 
not always replicated in human disease, and these findings 
now require robust validation in patients with inflammatory 
disease.
In this study, we demonstrate a profound and previously 
unrecognised role for pre- receptor metabolism and activa-
tion of GCs by the enzyme 11β-HSD1 in mediating the anti- 
inflammatory therapeutic actions of oral GCs. Consequently, 
this study adds significant insight into our mechanistic under-
standing of therapeutic GC action. Here, a greater aware-
ness of the how 11β-HSD1 targets the anti- inflammatory 
actions of therapeutic GCs at sites of inflammation may be 
able to inform the development of better- tolerated steroids 
that possess enhanced kinetics and activation efficiency by 
11β-HSD1 to improve targeting and dosing efficacy, as well 
as informing ongoing studies examining the application of 
therapeutic 11β-HSD1 inhibitors.
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